Cholecystokinin-induced antinociception is not blocked by CCK-A or CCK- B receptor antagonists

Peptides

Volumn 18, Issue 3, 1997, Pages 409-414

  Williams, Cynthia L ^a   Rosenfeld, Gary C ^a   Burks, Thomas F ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Antagonist; Antinociception; Cholecystokinin; Gastrointestinal transit; Mouse; Opioid

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; CHOLECYSTOKININ; CHOLECYSTOKININ A RECEPTOR; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; CHOLECYSTOKININ B RECEPTOR; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; CHOLECYSTOKININ RECEPTOR STIMULATING AGENT; DEVAZEPIDE; NALOXONE; OPIATE ANTAGONIST; OPIATE RECEPTOR; SNF 9007; SNF 9019; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG MECHANISM; GASTROINTESTINAL TRANSIT; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR AFFINITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANALGESIA; ANALGESICS; ANIMALS; CHOLECYSTOKININ; GASTROINTESTINAL TRANSIT; MALE; MICE; MICE, INBRED ICR; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ;

ANIMALIA;

EID: 0030971615     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0196-9781(96)00341-5     Document Type: Article

References (28)

1. Ayres E. A., Parkhurst D. N., Fang S.-N., Kramer T. H., Hruby V. J., Burks T. F. Antinociceptive and gastrointestinal effects of cholecystokinin (CCK-8) and related analogues of CCK-8 in the mouse. Proc. West. Pharmacol. Soc. 34:1991;477-484.
2. Baber N. S., Dourish C. T., Hill D. R. The role of CCK, caerulein, and CCK antagonists in antinociception. PAIN. 39:1989;307-328.
3. Barbaz B. S., Autry W. L., Ambrose F. G., Gerber R., Liebman J. M. Antagonism of cholecystokinin by naloxone and proglumide in mice. Ann. N.Y. Acad. Sci. 448:1985;573-574.
4. Barbaz B. S., Autry W. L., Ambrose F. G., Hall N. R., Liebman J. M. Antinociceptive profile of sulfated CCK-8. Comparison with CCK-4, unsulfated CCK-8, and other neuropeptides. Neuropharmacology. 25:1986;823-829.
5. Bock M. G., DiPadro M. R., Evans B. E., Rittle K. E., Whittler W. L., Veber D. F., Anderson P. S., Freidinger R. M. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L365,260. J. Med. Chem. 32:1989;13-16.
6. Chang R. S. L., Lotti V. J., Monaghan R. L., Birnbaum J., Stapely E. D., Goetz M. A., Albers-Schonberg G., Patchett A. A., Liesch J. M., Hensens D. D., Springer J. P. A potent nonpeptide cholecystokinin antagonist selective for peripheral tissues isolated from Aspergillus Alliaceus. Science. 230:1985;177-179.
7. Chang R. S. L., Lotti V. J. Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc. Natl. Acad. Sci. USA. 83:1986;4923-4926.
8. Gaudrea P., St-Pierre S., Pert C. B., Quirion R. CCK receptors in mammalian brain, a comparative characterization and visualization. Ann. N.Y. Acad. Sci. 448:1985;198-219.
9. Gaudrea P., Lavigne G. J., Quirion R. Cholecystokinin antagonists proglumide, lorglumide and benzotript, but not L-364,718, interact with brain opioid binding sites. Neuropeptides. 16:1990;51-55.
10. Haley T. J., McCormick W. G. Pharmacological effects produced by intracerebral injections of drugs into the conscious mouse. Br. J. Pharmacol. Chemother. 12:1957;12-15.
11. Hill R. G., Hughes J., Pittaway K. M. Antinociceptive action of cholecystokinin octapeptide (CCK 8) and related peptides in rats and mice: Effects of naloxone and peptidase inhibitors. Neuropharmacology. 26:1987;299-300.
12. Hong E. K., Takemori A. E. Indirect involvement of delta opioid receptors in cholecystokinin octapeptide-induced analgesia in mice. J. Pharmacol. Exp. Ther. 251:1989;594-598.
13. Hruby V. J., Fang S.-N., Knapp S. J., Kazmierski W., Lui G. K., Yamamura H. I. Cholecystokinin analogues with high affinity and selectivity for brain membrane receptors. Int. J. Peptide Prot. Res. 35:1990;566-573.
14. Jurna I., Zetler G. Antinociceptive effect of centrally administered caerulein and cholecystokinin octapeptide (CCK-8). Eur. J. Pharmacol. 73:1981;323-331.
15. 26-33): Evidence for CCK-B receptor heterogeneity. J. Pharmacol. Exp. Ther. 255:1990;1278-1285.
16. Kramer T. H., Fang S.-N., Davis P., Parkhurst D., Hruby V. J., Burks T. F. Analogues of CCK 26-33 selective for B-type CCK receptors possess delta opioid receptor activity in vitro and in vivo. (Abstract). FASEB J. 5:1991;A473.
17. Miller M., Galligan J. J., Burks T. F. Acurate measurement of intestinal transit in the rat. J. Pharm. Methods. 6:1981;211-217.
18. Pittaway K. M., Rodriguez R. E., Hughes J., Hill R. G. CCK-8 analgesia and hyperalgesia after intrathecal administration in the rat: Comparison with CCK-related peptides. Neuropeptides. 10:1987;87-108.
19. Porreca F., Mosberg H. I., Hurst R., Hruby V. J., Burks T. F. Roles of mu, delta, and kappa opioid receptors in spinal and supraspinal mediation of gastrointestinal transit effects and hot plate analgesia in the mouse. J. Pharmacol. Exp. Ther. 230:1984;341-348.
20. Rattray M., Joran C. C., De Belleroche J. The novel CCK antagonist L364,718 abolished caerulein- but potentiates morphine-induced antinociception. Eur. J. Pharmacol. 152:1988;163-166.
21. Rezvani A., Stokes K. B., Rhoads D. L., Way E. L. Proglumide exhibits delta opioid agonist properties. Alcohol Drug Res. 7:1987;135-146.
22. Slaninova J., Knapp R. J., Wu J., Fang S.-N., Kramer T., Burks T. F., Hruby V. J., Yamamura H. I. Opioid receptor binding properties of analgesic analogues of cholecystokinin octapeptide. Eur. J. Pharmacol. 200:1991;195-198.
23. Stengaard-Pederson K., Larsson L. I. Localization and opiate receptor binding of enkephalin, CCK, and ACTH/ β -endorphin in the rat central nervous system. Peptides. 2:((Suppl 1)):1981;3-21.
24. Tallarida R. J., Murray R. B. Manual of pharmacologic calculations with computer programs. 1987;Springer-Verlag, New York.
25. 3H-etorphine binding to rat brain opiate receptors. Life Sci. 45:1989;117-123.
26. Wang X.-J., Han J.-S. Modification of cholecystokinin octapeptide of the binding of mu, delta, and kappa opioid receptors. J. Neurochem. 55:1990;1379-1382.
27. Williams C. L., Rosenfeld G. C., Dafny N., Fang S.-N., Hruby V. J., Bowden G., Cullinan C. A., Burks T. F. SNF9007: A novel analgesic that acts simultaneously at delta-1, delta-2 and mu opioid receptors. J. Pharmacol. Exp. Ther. 269:1994;750-755.
28. Zetler G. Analgesia and ptosis caused by caerulein and cholecystokinin octapeptide (CCK-8). Neuropharmacology. 19:1980;415-422.